Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)

Summary

This is a Phase II clinical study for people with stage IV cancer. The study will evaluate the use of stereotactic body radiation therapy (SBRT), a type of focused radiation treatment, together with immunotherapy-based treatment. SRBT will be used to treat multiple areas of cancer that have spread to other parts of the body. The study will evaluate whether this treatment approach can be safely given while patients continue their planned cancer treatment and may help control their cancer.

Eligibility

Age range

18–99 years

Sex

All

Healthy volunteers

No

Interventions

• Radiation
  Stereotactic Body Radiation Therapy (SBRT)

  SBRT administered to 6-10 metastatic lesions during the first cycle of immunotherapy.

• Drug
  Pembrolizumab

  FDA-approved immune checkpoint inhibitor administered according to standard clinical practice and disease-specific indications.

• Drug
  Nivolumab

  FDA-approved immune checkpoint inhibitor administered according to standard clinical practice and disease-specific indications.

• Drug
  Atezolizumab

  FDA-approved immune checkpoint inhibitor administered according to clinical practice and disease-specific indications.

• Drug
  Ipilimumab

  FDA-approved immune checkpoint inhibitor administered according to standard clinical practice and disease-specific indications.

Location